SEC INSIDER TRANSACTIONS

ABBOTT LABORATORIES (ABT) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

ABT · ABBOTT LABORATORIES

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 19 filings · fetched 2026-11-13T16:19:18Z

Recent reported activity

0purchase rows on this page

5sale rows on this page

26matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-05Filed 2026-11-06	Moreland Mary KOfficer · EXECUTIVE VICE PRESIDENT Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Balance in the Abbott Laboratories Stock Retirement Trust as of November 5, 2026. References:	S Sale (market/private)Common shares without par value · Non-derivative	3,500D	116	Direct	Form 4 ↗0001783147-26-000013
2026-09-30Filed 2026-10-02	Conroy Kevin TDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	318A	98.83	Direct	Form 4 ↗0001104659-26-113286
2026-09-30Filed 2026-10-02	Ahuja NitaDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	318A	98.83	Direct	Form 4 ↗0001104659-26-113285
2026-09-30Filed 2026-10-02	Roman Michael FDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	381A	98.83	Direct	Form 4 ↗0001104659-26-113280
2026-09-30Filed 2026-10-02	Gonzalez Patricia PaolaDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	333A	98.83	Direct	Form 4 ↗0001104659-26-113287
2026-09-30Filed 2026-10-02	Stratton John GDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	397A	98.83	Direct	Form 4 ↗0001104659-26-113291
2026-09-23Filed 2026-09-25	Conroy Kevin TDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	F WithholdingCommon shares without par value · Non-derivative	52,507D	103.99	Direct	Form 4 ↗0001306119-26-000009
2026-09-02Filed 2026-09-03	MCCOY JOHN A. JR.Officer · VICE PRESIDENT AND CONTROLLER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2026. References:	S Sale (market/private)Common shares without par value · Non-derivative	27D	109.54	Direct	Form 4 ↗0001644207-26-000012
2026-09-01Filed 2026-09-03	Boudreau Philip POfficer · EVP AND CFO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2026. References:	F WithholdingCommon shares without par value · Non-derivative	388D	110.36	Direct	Form 4 ↗0001805099-26-000008
2026-09-01Filed 2026-09-03	MCCOY JOHN A. JR.Officer · VICE PRESIDENT AND CONTROLLER Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2026. References:	F WithholdingCommon shares without par value · Non-derivative	52D	110.36	Direct	Form 4 ↗0001644207-26-000012
2026-08-25Filed 2026-08-27	Ford Robert BDirector · Officer · CHAIRMAN AND CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. F4 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. F5 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. References: F5	M Exercise / conversionOption (right to buy) · Derivative	246,963D	0	Direct	Form 4 ↗0001612571-26-000011
2026-08-25Filed 2026-08-27	Ford Robert BDirector · Officer · CHAIRMAN AND CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. F4 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. F5 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. References: F4	M Exercise / conversionOption (right to buy) · Derivative	151,869D	0	Direct	Form 4 ↗0001612571-26-000011
2026-08-25Filed 2026-08-27	Ford Robert BDirector · Officer · CHAIRMAN AND CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. F4 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. F5 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. References: F2	S Sale (market/private)Common shares without par value · Non-derivative	180,297D	116.19	Direct	Form 4 ↗0001612571-26-000011
2026-08-25Filed 2026-08-27	Ford Robert BDirector · Officer · CHAIRMAN AND CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. F4 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. F5 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. References: F1	S Sale (market/private)Common shares without par value · Non-derivative	218,535D	115.57	Direct	Form 4 ↗0001612571-26-000011
2026-08-25Filed 2026-08-27	Ford Robert BDirector · Officer · CHAIRMAN AND CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. F4 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. F5 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. References:	M Exercise / conversionCommon shares without par value · Non-derivative	246,963A	59.94	Direct	Form 4 ↗0001612571-26-000011
2026-08-25Filed 2026-08-27	Ford Robert BDirector · Officer · CHAIRMAN AND CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. F4 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. F5 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. References:	M Exercise / conversionCommon shares without par value · Non-derivative	151,869A	44.4	Direct	Form 4 ↗0001612571-26-000011
2026-08-12Filed 2026-08-13	Morrone Louis H.Officer · EXECUTIVE VICE PRESIDENT Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	I Other reported codeCommon shares without par value · Non-derivative	12D	107.99	IndirectProfit Sharing Trust	Form 4 ↗0001867666-26-000013
2026-08-11Filed 2026-08-13	Morrone Louis H.Officer · EXECUTIVE VICE PRESIDENT Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	S Sale (market/private)Common shares without par value · Non-derivative	5,850D	109.83	Direct	Form 4 ↗0001867666-26-000013
2026-06-30Filed 2026-07-01	Ahuja NitaDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	347A	90.74	Direct	Form 4 ↗0002102715-26-000006
2026-06-30Filed 2026-07-01	Gonzalez Patricia PaolaDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	363A	90.74	Direct	Form 4 ↗0001879701-26-000008
2026-06-30Filed 2026-07-01	Morrone Louis H.Officer · EXECUTIVE VICE PRESIDENT Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Balance in the Abbott Laboratories Stock Retirement Trust as of June 30, 2026. References:	F WithholdingCommon shares without par value · Non-derivative	269D	92.71	Direct	Form 4 ↗0001867666-26-000009
2026-06-30Filed 2026-07-01	Roman Michael FDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	416A	90.74	Direct	Form 4 ↗0001577544-26-000010
2026-06-30Filed 2026-07-01	Stratton John GDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. References: F1, F2	A Award / grantStock Equivalent Units · Derivative	432A	90.74	Direct	Form 4 ↗0001385262-26-000019
2026-06-30Filed 2026-07-01	Conroy Kevin TDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. References: F1	A Award / grantStock Equivalent Units · Derivative	231A	90.74	Direct	Form 4 ↗0001306119-26-000006
2026-06-27Filed 2026-06-29	Cushman Elizabeth C.Officer · EVP, GC AND SECRETARY Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	F WithholdingCommon shares without par value · Non-derivative	560D	94.12	Direct	Form 4 ↗0002075371-26-000009

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.